PDCD1 and cancer: The discovery of immune checkpoints has exposed new targets for the treatment of malignant tumors, such as immune checkpoint inhibition (ICI) therapy for programmed cell death protein 1 (PD‐1) and its ligand PD‐L1.4, 5